N/A Archives - Advanced Medical Solutions https://admedsol.com/message-type/n-a/ Thu, 31 Aug 2023 13:46:23 +0000 en-US hourly 1 https://wordpress.org/?v=6.9.4 https://admedsol.com/wp-content/uploads/2026/02/cropped-Web-Icon-32x32.png N/A Archives - Advanced Medical Solutions https://admedsol.com/message-type/n-a/ 32 32 Director/PDMR and PCA Shareholding https://admedsol.com/regulatory-news-announcements/directorpdmr-and-pca-shareholding/ Mon, 18 Jul 2016 14:57:38 +0000 https://admedsol.wpengine.com/investor-relations/regulatory-news-announcements/no-rid-2875/ RNS Number : 4901E Advanced Medical Solutions Grp PLC 18 July 2016     18 July 2016             Advanced Medical Solutions Group plc (“AMS”, the “Company” or the “Group”)               Director/PDMR and PCA Shareholding   Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), a leading developer and manufacturer of advanced products for the […]

The post Director/PDMR and PCA Shareholding appeared first on Advanced Medical Solutions.

]]> RNS Number : 4901E
Advanced Medical Solutions Grp PLC
18 July 2016
 

 

18 July 2016

            Advanced Medical Solutions Group plc

(“AMS”, the “Company” or the “Group”)

 

            Director/PDMR and PCA Shareholding

 

Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), a leading developer and manufacturer of advanced products for the global surgical and wound care markets, announces that it was notified on 14 July 2016 that Simon Coates, a Senior Manager and PDMR, had exercised 16,188 Ordinary Shares of 5p from the Deferred Share Bonus Plan, sold 5,768 shares from the total shares exercised (to satisfy income tax/National Insurance liabilities) and transferred 10,420 shares to Angela Coates (Simon Coates’s wife). In addition Simon Coates transferred 10,000 shares held in his name to a nominee account.

 

AMS was also notified that Pieter van Hoof, a Senior Manager and PDMR, had exercised 25,000 Ordinary Shares of 5p from the Long-Term Investment Plan and sold 11,809 shares from the total shares exercised (to satisfy income tax/National Insurance liabilities).

 

The two notifications below, made in accordance with the requirements of the EU Market Abuse Regulation, provide further detail.

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

 

1.

Details of the person discharging managerial responsibilities/person closely associated

a)

Name: Simon Coates

2.

Reason for the notification

a)

Position/status: Senior Manager/PDMR

b)

Initial notification/Amendment: Initial Notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name:   Advanced Medical Solutions Group plc

b)

LEI: 213800HJP6OWOSZI1L74

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument: Ordinary Shares of 5p

Identification code: GB0004536594

b)

Nature of the transaction:

·      Exercise of 16,188 Ordinary Shares of 5p from the Deferred Share Bonus Plan;

·      Sale of 5,768 shares from the total shares exercised (to satisfy income tax/National Insurance liabilities);

·      Transfer of 10,420 shares to Angela Coates (Simon Coates’s wife); and

·      Transfer of 10,000 shares to a nominee account.

c)

Price(s) and volume(s):

Exercise of Deferred Share Bonus Plan:

Price(s)

Volume(s)

Nil consideration

16,188

Sale of shares:

Price(s)

Volume(s)

£1.983547

5,768

Transfer to Angela Coates:

Price(s)

Volume(s)

Nil consideration

10,420

Transfer to a nominee account:

Price(s)

Volume(s)

Nil consideration

10,000

d)

Aggregated information: (Relates to those shares sold only)

Aggregated volume: 5,768

Aggregated price: £1.983547

e)

Date of the transaction: 14/07/2016

f)

Place of the transaction: London Stock Exchange, AIM Market (XLON)

 

1.

Details of the person discharging managerial responsibilities/person closely associated

a)

Name: Pieter van Hoof

2.

Reason for the notification

a)

Position/status: Senior Manager/PDMR

b)

Initial notification/Amendment: Initial Notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name:   Advanced Medical Solutions Group plc

b)

LEI: 213800HJP6OWOSZI1L74

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument: Ordinary Shares of 5p

Identification code: GB0004536594

b)

Nature of the transaction:

·      Exercise of 25,000 Ordinary Shares of 5p from the Long-Term Investment Plan; and

·      Sale of 11,809 shares from the total shares exercised (to satisfy income tax/National Insurance liabilities).

c)

Price(s) and volume(s):

Exercise of options:

Price(s)

Volume(s)

£1 total consideration

25,000

Sale of shares:

Price(s)

Volume(s)

£1.983547

11,809

d)

Aggregated information: (relates to sale shares only)

Aggregated volume: 11,809

Aggregated price: £1.983547

e)

Date of the transaction: 14/07/2016

f)

Place of the transaction: London Stock Exchange, AIM Market (XLON)

 

– End –

 

For further information, please visit www.admedsol.com or contact:

 

Advanced Medical Solutions Group plc

Tel: +44 (0) 1606 545508

Chris Meredith, Chief Executive Officer

Mary Tavener, Group Finance Director




Consilium Strategic Communications

Tel: +44 (0) 20 3709 5700

Mary-Jane Elliott / Jonathan Birt / Matthew Neal / Hendrik Thys

AMS@consilium-comms.com



Investec Bank PLC (NOMAD & Broker)

Tel: +44 (0) 20 7597 5970

Gary Clarence / Daniel Adams / Patrick Robb


 

About Advanced Medical Solutions Group plc – see www.admedsol.com

AMS is a world-leading independent developer and manufacturer of innovative and technologically advanced products for the global surgical, wound care and wound closure markets, focused on quality outcomes for patients and value for payors. AMS has a wide range of products that include silver alginates, alginates, foams, tissue adhesives, sutures and haemostats, which it markets under its brands; ActivHeal®, LiquiBand® and RESORBA® as well as supplying under white label.

AMS’s products, manufactured out of two sites in the UK, one in the Netherlands, two in Germany and one in the Czech Republic, are sold in more than 70 countries via a network of multinational or regional partners and distributors, as well as via AMS’s own direct sales forces in the UK, Germany, the Czech Republic and Russia.  Established in 1991, the Company has 510 employees.  For more information please see www.admedsol.com.


This information is provided by RNS
The company news service from the London Stock Exchange
 

END

 
 

DSHLLFEVDRITLIR

The post Director/PDMR and PCA Shareholding appeared first on Advanced Medical Solutions.

]]> Directors’ Shareholdings https://admedsol.com/regulatory-news-announcements/directors-shareholdings/ Wed, 04 May 2016 07:00:10 +0000 https://admedsol.wpengine.com/investor-relations/regulatory-news-announcements/no-rid-2773/ RNS Number : 1361X Advanced Medical Solutions Grp PLC 04 May 2016   4 May 2016 Advanced Medical Solutions Group plc (“AMS” or the “Group”)   Directors’ Shareholdings   Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), a leading developer and manufacturer of advanced products for the global surgical and wound care markets, announces […]

The post Directors’ Shareholdings appeared first on Advanced Medical Solutions.

]]> RNS Number : 1361X
Advanced Medical Solutions Grp PLC
04 May 2016
 

4 May 2016

Advanced Medical Solutions Group plc

(“AMS” or the “Group”)

 

Directors’ Shareholdings

 

Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), a leading developer and manufacturer of advanced products for the global surgical and wound care markets, announces that the Trust which manages the Deferred Share Bonus Plan on behalf of the employees of AMS has purchased ordinary shares of 5 pence each (“Ordinary Shares”) on 3 May 2016, at a price of 183 pence per share on behalf of Chris Meredith and Mary Tavener as part of the Deferred Share Bonus Plan and, under the terms of the Plan, these shares will be held in trust on their behalf.

 

Following these transactions the beneficial ownership of Chris Meredith and Mary Tavener is as follows:

 

Director

Date purchased

Shares purchased

Resultant holding

% of issued share capital

Chris Meredith

Chief Executive Officer

3 May 2016

2,431

1,190,322

0.6

Mary Tavener

Chief Financial Officer

3 May 2016

2,431

1,828,129

0.9

 

 

–     Ends –

 

 

For further information, please visit www.admedsol.com or contact:

 

Advanced Medical Solutions Group plc

Tel: +44 (0) 1606 545508

Chris Meredith, Chief Executive Officer

Mary Tavener, Group Finance Director




Consilium Strategic Communications

Tel: +44 (0) 20 3709 5700

Mary-Jane Elliott / Jonathan Birt / Matthew Neal / Hendrik Thys




Investec Bank PLC (NOMAD & Broker)

Tel: +44 (0) 20 7597 5970

Gary Clarence / Daniel Adams / Patrick Robb


 

 

About Advanced Medical Solutions Group plc

AMS is a world-leading independent developer and manufacturer of innovative and technologically advanced products for the global surgical, wound care and wound closure markets, focused on quality outcomes for patients and value for payors. AMS has a wide range of products that include silver alginates, alginates, foams, tissue adhesives, sutures and haemostats, which it markets under its brands; ActivHeal®, LiquiBand® and RESORBA® as well as supplying under white label.
AMS’s products, manufactured out of two sites in the UK, one in the Netherlands, two in Germany and one in the Czech Republic, are sold in more than 70 countries via a network of multinational or regional partners and distributors, as well as via AMS’s own direct sales forces in the UK, Germany, the Czech Republic and Russia.  Established in 1991, the Company has 510 employees.  For more information please see www.admedsol.com.


This information is provided by RNS
The company news service from the London Stock Exchange
 

END

 
 

DSHLLFIDEIIVIIR

The post Directors’ Shareholdings appeared first on Advanced Medical Solutions.

]]> Director/PDMR Shareholding https://admedsol.com/regulatory-news-announcements/directorpdmr-shareholding-2/ Tue, 19 Apr 2016 10:58:47 +0000 https://admedsol.wpengine.com/investor-relations/regulatory-news-announcements/no-rid-2755/ RNS Number : 6473V Advanced Medical Solutions Grp PLC 19 April 2016   19 April 2016 Advanced Medical Solutions Group plc (“AMS” or the “Group”)   Directors’ Shareholdings   Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), a leading developer and manufacturer of advanced products for the global surgical and wound care markets, announces […]

The post Director/PDMR Shareholding appeared first on Advanced Medical Solutions.

]]> RNS Number : 6473V
Advanced Medical Solutions Grp PLC
19 April 2016
 

19 April 2016

Advanced Medical Solutions Group plc

(“AMS” or the “Group”)

 

Directors’ Shareholdings

 

Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), a leading developer and manufacturer of advanced products for the global surgical and wound care markets, announces that the Board, following a recommendation from the Remuneration Committee, has granted new share options to the following Directors under the Advanced Medical Solutions Long Term Incentive Plan (the ‘LTIP’) on 18 April 2016.  The vesting period of these options is subject to certain performance criteria over a three year period.

 

Director

Options prior to grant

Options granted

Resultant holding

Chris Meredith

Chief Executive Officer

938,439

143,553

1,081,992

Mary Tavener

Chief Financial Officer

568,155

111,050

679,205

 

Advanced Medical Solutions Group plc also announces that on 18 April 2016, the Board, following a recommendation from the Remuneration Committee, granted new share options to the following Directors under the Advanced Medical Solutions Deferred Annual Bonus Plan (the ‘2014 DAB’).

 

This award is in respect of the part of their bonus that the Directors are compulsorily required to defer for the 2015 financial year. These options vest at the end of three years.

 

Director

Options prior to grant

Options granted

Resultant holding

Chris Meredith

Chief Executive Officer

49,580

32,638

82,218

Mary Tavener

Chief Financial Officer

36,538

21,332

57,870

 

–     Ends –

 

 

 

For further information, please visit www.admedsol.com or contact:

 

Advanced Medical Solutions Group plc

Tel: +44 (0) 1606 545508

Chris Meredith, Chief Executive Officer

Mary Tavener, Group Finance Director




Consilium Strategic Communications

Tel: +44 (0) 20 3709 5700

Mary-Jane Elliott / Jonathan Birt / Matthew Neal / Hendrik Thys




Investec Bank PLC (NOMAD & Broker)

Tel: +44 (0) 20 7597 5970

Gary Clarence / Daniel Adams / Patrick Robb


 

About Advanced Medical Solutions Group plc

AMS is a world-leading independent developer and manufacturer of innovative and technologically advanced products for the global surgical, wound care and wound closure markets, focused on quality outcomes for patients and value for payors. AMS has a wide range of products that include silver alginates, alginates, foams, tissue adhesives, sutures and haemostats, which it markets under its brands; ActivHeal®, LiquiBand® and RESORBA® as well as supplying under white label.
AMS’s products, manufactured out of two sites in the UK, one in the Netherlands, two in Germany and one in the Czech Republic, are sold in more than 70 countries via a network of multinational or regional partners and distributors, as well as via AMS’s own direct sales forces in the UK, Germany, the Czech Republic and Russia.  Established in 1991, the Company has 510 employees.  For more information please see www.admedsol.com.


This information is provided by RNS
The company news service from the London Stock Exchange
 

END

 
 

DSHGCGDSRUBBGLC

The post Director/PDMR Shareholding appeared first on Advanced Medical Solutions.

]]> Total Voting Rights https://admedsol.com/regulatory-news-announcements/total-voting-rights-3/ Fri, 30 Oct 2015 10:16:35 +0000 https://admedsol.wpengine.com/investor-relations/regulatory-news-announcements/no-rid-2320/ RNS Number : 0025E Advanced Medical Solutions Grp PLC 30 October 2015    30 October 2015 Advanced Medical Solutions Group plc (“AMS” or the “Group”)   Total Voting Rights   In accordance with Disclosure and Transparency Rule 5.6.1, the issued share capital of Advanced Medical Solutions Group plc as at 30 October 2015 comprises […]

The post Total Voting Rights appeared first on Advanced Medical Solutions.

]]> RNS Number : 0025E
Advanced Medical Solutions Grp PLC
30 October 2015
 



30 October 2015

Advanced Medical Solutions Group plc

(“AMS” or the “Group”)

 

Total Voting Rights

 

In accordance with Disclosure and Transparency Rule 5.6.1, the issued share capital of Advanced Medical Solutions Group plc as at 30 October 2015 comprises 208,885,733 ordinary shares of 5p each with voting rights. There are no shares held in treasury.

 

The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA’s Disclosure and Transparency Rules.

 

–     Ends –

 

For further information, please visit www.admedsol.com or contact:

 

Advanced Medical Solutions Group plc

Tel: +44 (0) 1606 545508

Chris Meredith, Chief Executive Officer

Mary Tavener, Group Finance Director




Consilium Strategic Communications

Tel: +44 (0) 20 3709 5700

Mary-Jane Elliott / Jonathan Birt / Matthew Neal / Ivar Milligan




Investec Bank PLC (NOMAD & Broker)

Tel: +44 (0) 20 7597 5970

Gary Clarence / Daniel Adams / Patrick Robb


 

About Advanced Medical Solutions Group plc – see www.admedsol.com 

AMS is a world-leading independent developer and manufacturer of innovative and technologically advanced products for the global surgical, wound care and wound closure markets, focused on quality outcomes for patients and value for payors. AMS has a wide range of products that include silver alginates, alginates, foams, tissue adhesives, sutures and haemostats, which it markets under its brands ActivHeal®, LiquiBand® and RESORBA® as well as supplying under white label.

AMS’s products, manufactured out of two sites in the UK, one in the Netherlands, two in Germany and one in the Czech Republic, are sold in 65 countries via a network of multinational or regional partners and distributors, as well as via AMS’s own direct sales forces in the UK, Germany, the Czech Republic and Russia.  Established in 1991, the Group has approximately 470 employees.  For more information please see www.admedsol.com.

 


This information is provided by RNS
The company news service from the London Stock Exchange
 

END

 
 

TVREAEEEDFLSFFF

The post Total Voting Rights appeared first on Advanced Medical Solutions.

]]> Total Voting Rights https://admedsol.com/regulatory-news-announcements/total-voting-rights-2/ Wed, 30 Sep 2015 15:40:15 +0000 https://admedsol.wpengine.com/investor-relations/regulatory-news-announcements/no-rid-2097/ RNS Number : 7969A Advanced Medical Solutions Grp PLC 30 September 2015    30 September 2015 Advanced Medical Solutions Group plc (“AMS” or the “Group”)   Total Voting Rights   In accordance with Disclosure and Transparency Rule 5.6.1, the issued share capital of Advanced Medical Solutions Group plc as at 30 September 2015 comprises […]

The post Total Voting Rights appeared first on Advanced Medical Solutions.

]]> RNS Number : 7969A
Advanced Medical Solutions Grp PLC
30 September 2015
 



30 September 2015

Advanced Medical Solutions Group plc

(“AMS” or the “Group”)

 

Total Voting Rights

 

In accordance with Disclosure and Transparency Rule 5.6.1, the issued share capital of Advanced Medical Solutions Group plc as at 30 September 2015 comprises 208,860,733 ordinary shares of 5p each with voting rights. There are no shares held in treasury.

 

The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA’s Disclosure and Transparency Rules.

 

–     Ends –

 

For further information, please visit www.admedsol.com or contact:

 

Advanced Medical Solutions Group plc

Tel: +44 (0) 1606 545508

Chris Meredith, Chief Executive Officer

Mary Tavener, Group Finance Director




Consilium Strategic Communications

Tel: +44 (0) 20 3709 5700

Mary-Jane Elliott / Jonathan Birt / Matthew Neal / Ivar Milligan




Investec Bank PLC (NOMAD & Broker)

Tel: +44 (0) 20 7597 5970

Gary Clarence / Daniel Adams / Patrick Robb


 

About Advanced Medical Solutions Group plc – see www.admedsol.com 

AMS is a world-leading independent developer and manufacturer of innovative and technologically advanced products for the global surgical, wound care and wound closure markets, focused on quality outcomes for patients and value for payors. AMS has a wide range of products that include silver alginates, alginates, foams, tissue adhesives, sutures and haemostats, which it markets under its brands ActivHeal®, LiquiBand® and RESORBA® as well as supplying under white label.

AMS’s products, manufactured out of two sites in the UK, one in the Netherlands, two in Germany and one in the Czech Republic, are sold in 65 countries via a network of multinational or regional partners and distributors, as well as via AMS’s own direct sales forces in the UK, Germany, the Czech Republic and Russia.  Established in 1991, the Group has approximately 470 employees.  For more information please see www.admedsol.com.

 


This information is provided by RNS
The company news service from the London Stock Exchange
 

END

 
 

TVREALNEDDNSEFF

The post Total Voting Rights appeared first on Advanced Medical Solutions.

]]> Total Voting Rights https://admedsol.com/regulatory-news-announcements/total-voting-rights/ Tue, 30 Jun 2015 16:10:36 +0000 https://admedsol.wpengine.com/investor-relations/regulatory-news-announcements/no-rid-1503/ RNS Number : 7184R Advanced Medical Solutions Grp PLC 30 June 2015    30 June 2015 Advanced Medical Solutions Group plc (“AMS” or the “Group”)   Total Voting Rights   In accordance with Disclosure and Transparency Rule 5.6.1, the issued share capital of Advanced Medical Solutions Group plc as at 30 June 2015 comprises […]

The post Total Voting Rights appeared first on Advanced Medical Solutions.

]]> RNS Number : 7184R
Advanced Medical Solutions Grp PLC
30 June 2015
 



30 June 2015

Advanced Medical Solutions Group plc

(“AMS” or the “Group”)

 

Total Voting Rights

 

In accordance with Disclosure and Transparency Rule 5.6.1, the issued share capital of Advanced Medical Solutions Group plc as at 30 June 2015 comprises 208,650,793 ordinary shares of 5p each with voting rights. There are no shares held in treasury.

 

The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA’s Disclosure and Transparency Rules.

 

–     Ends –

 

For further information, please visit www.admedsol.com or contact:

 

Advanced Medical Solutions Group plc

Tel: +44 (0) 1606 545508

Chris Meredith, Chief Executive Officer

Mary Tavener, Group Finance Director




Consilium Strategic Communications

Tel: +44 (0) 20 3709 5700

Mary-Jane Elliott / Jonathan Birt / Matthew Neal / Ivar Milligan




Investec Bank PLC (NOMAD & Broker)

Tel: +44 (0) 20 7597 5970

Gary Clarence / Daniel Adams / Patrick Robb


 

About Advanced Medical Solutions Group plc – see www.admedsol.com 

AMS is a world-leading independent developer and manufacturer of innovative and technologically advanced products for the global surgical, wound care and wound closure markets, focused on quality outcomes for patients and value for payors. AMS has a wide range of products that include silver alginates, alginates, foams, tissue adhesives, sutures and haemostats, which it markets under its brands ActivHeal®, LiquiBand® and RESORBA® as well as supplying under white label.

AMS’s products, manufactured out of two sites in the UK, one in the Netherlands, two in Germany and one in the Czech Republic, are sold in 65 countries via a network of multinational or regional partners and distributors, as well as via AMS’s own direct sales forces in the UK, Germany, the Czech Republic and Russia.  Established in 1991, the Group has approximately 470 employees.  For more information please see www.admedsol.com.

 


This information is provided by RNS
The company news service from the London Stock Exchange
 

END

 
 

TVREASKEDEXSEFF

The post Total Voting Rights appeared first on Advanced Medical Solutions.

]]> Total Voting Rights https://admedsol.com/regulatory-news-announcements/total-voting-rights-55/ Fri, 29 May 2015 16:37:14 +0000 https://admedsol.wpengine.com/investor-relations/shareholder/regulatory-news-announcements/1020/ RNS Number : 7077O Advanced Medical Solutions Grp PLC 29 May 2015    29 May 2015 Advanced Medical Solutions Group plc (“AMS” or the “Group”)   Total Voting Rights   In accordance with Disclosure and Transparency Rule 5.6.1, the issued share capital of Advanced Medical Solutions Group plc as at 29 May 2015 comprises […]

The post Total Voting Rights appeared first on Advanced Medical Solutions.

]]> RNS Number : 7077O
Advanced Medical Solutions Grp PLC
29 May 2015
 



29 May 2015

Advanced Medical Solutions Group plc

(“AMS” or the “Group”)

 

Total Voting Rights

 

In accordance with Disclosure and Transparency Rule 5.6.1, the issued share capital of Advanced Medical Solutions Group plc as at 29 May 2015 comprises 208,226,634 ordinary shares of 5p each with voting rights. There are no shares held in treasury.

 

The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA’s Disclosure and Transparency Rules.

 

–     Ends –

 

For further information, please visit www.admedsol.com or contact:

 

Advanced Medical Solutions Group plc

Tel: +44 (0) 1606 545508

Chris Meredith, Chief Executive Officer

Mary Tavener, Group Finance Director




Consilium Strategic Communications

Tel: +44 (0) 20 3709 5700

Mary-Jane Elliott / Jonathan Birt / Matthew Neal / Ivar Milligan




Investec Bank PLC (NOMAD & Broker)

Tel: +44 (0) 20 7597 5970

Gary Clarence / Daniel Adams / Patrick Robb


 

About Advanced Medical Solutions Group plc – see www.admedsol.com 

AMS is a world-leading independent developer and manufacturer of innovative and technologically advanced products for the global surgical, wound care and wound closure markets, focused on quality outcomes for patients and value for payors. AMS has a wide range of products that include silver alginates, alginates, foams, tissue adhesives, sutures and haemostats, which it markets under its brands ActivHeal®, LiquiBand® and RESORBA® as well as supplying under white label.

AMS’s products, manufactured out of two sites in the UK, one in the Netherlands, two in Germany and one in the Czech Republic, are sold in 65 countries via a network of multinational or regional partners and distributors, as well as via AMS’s own direct sales forces in the UK, Germany, the Czech Republic and Russia.  Established in 1991, the Group has approximately 470 employees.  For more information please see www.admedsol.com.

 


This information is provided by RNS
The company news service from the London Stock Exchange
 

END

 
 

TVREASSNADASEFF

The post Total Voting Rights appeared first on Advanced Medical Solutions.

]]> Total Voting Rights https://admedsol.com/regulatory-news-announcements/total-voting-rights-56/ Thu, 30 Apr 2015 12:08:03 +0000 https://admedsol.wpengine.com/investor-relations/shareholder/regulatory-news-announcements/1026/ RNS Number : 8655L Advanced Medical Solutions Grp PLC 30 April 2015    30 April 2015   Advanced Medical Solutions Group plc (the “Company”)   Total Voting Rights   In accordance with Disclosure and Transparency Rule 5.6.1, the issued share capital of Advanced Medical Solutions Group plc as at 30 April 2015 comprises 208,050,121 […]

The post Total Voting Rights appeared first on Advanced Medical Solutions.

]]> RNS Number : 8655L
Advanced Medical Solutions Grp PLC
30 April 2015
 



30 April 2015

 

Advanced Medical Solutions Group plc (the “Company”)

 

Total Voting Rights

 

In accordance with Disclosure and Transparency Rule 5.6.1, the issued share capital of Advanced Medical Solutions Group plc as at 30 April 2015 comprises 208,050,121 ordinary shares of 5p each with voting rights. There are no shares held in treasury.

 

The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA’s Disclosure and Transparency Rules.

 

 

For further information:

 

Mary Tavener, Finance Director                           +44 (0) 1606 545 508

 


This information is provided by RNS
The company news service from the London Stock Exchange
 

END

 
 

TVREAFLEDEXSEFF

The post Total Voting Rights appeared first on Advanced Medical Solutions.

]]> Total Voting Rights https://admedsol.com/regulatory-news-announcements/total-voting-rights-57/ Fri, 02 Jan 2015 08:15:58 +0000 https://admedsol.wpengine.com/investor-relations/shareholder/regulatory-news-announcements/1037/ RNS Number : 1402B Advanced Medical Solutions Grp PLC 02 January 2015    31 December 2014   Advanced Medical Solutions Group plc (the “Company”)   Total Voting Rights   In accordance with Disclosure and Transparency Rule 5.6.1, the issued share capital of Advanced Medical Solutions Group plc as at 31 December 2014 comprises 207,853,192 […]

The post Total Voting Rights appeared first on Advanced Medical Solutions.

]]> RNS Number : 1402B
Advanced Medical Solutions Grp PLC
02 January 2015
 



31 December 2014

 

Advanced Medical Solutions Group plc (the “Company”)

 

Total Voting Rights

 

In accordance with Disclosure and Transparency Rule 5.6.1, the issued share capital of Advanced Medical Solutions Group plc as at 31 December 2014 comprises 207,853,192 ordinary shares of 5p each with voting rights. There are no shares held in treasury.

 

The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA’s Disclosure and Transparency Rules.

 

 

For further information:

 

Mary Tavener, Finance Director                           +44 (0) 1606 545 508

 


This information is provided by RNS
The company news service from the London Stock Exchange
 

END

 
 

TVREAPFAEFSSEEF

The post Total Voting Rights appeared first on Advanced Medical Solutions.

]]> Total Voting Rights https://admedsol.com/regulatory-news-announcements/total-voting-rights-50/ Fri, 31 Oct 2014 15:18:21 +0000 https://admedsol.wpengine.com/investor-relations/shareholder/regulatory-news-announcements/996/ RNS Number : 8808V Advanced Medical Solutions Grp PLC 31 October 2014    31 October 2014   Advanced Medical Solutions Group plc (the “Company”)   Total Voting Rights   In accordance with Disclosure and Transparency Rule 5.6.1, the issued share capital of Advanced Medical Solutions Group plc as at 31 October 2014 comprises 207,806,853 […]

The post Total Voting Rights appeared first on Advanced Medical Solutions.

]]> RNS Number : 8808V
Advanced Medical Solutions Grp PLC
31 October 2014
 



31 October 2014

 

Advanced Medical Solutions Group plc (the “Company”)

 

Total Voting Rights

 

In accordance with Disclosure and Transparency Rule 5.6.1, the issued share capital of Advanced Medical Solutions Group plc as at 31 October 2014 comprises 207,806,853 ordinary shares of 5p each with voting rights. There are no shares held in treasury.

 

The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA’s Disclosure and Transparency Rules.

 

 

For further information:

 

Mary Tavener, Finance Director                           +44 (0) 1606 545 508

 


This information is provided by RNS
The company news service from the London Stock Exchange
 

END

 
 

TVREASEFDFPLFFF

The post Total Voting Rights appeared first on Advanced Medical Solutions.

]]>